Authors

Latest:

CTCL Today: Remaining Unmet Needs in CTCL

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

Hemali Batra-Sharma, M

Latest:

Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast Cancer

Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Christiane Querfeld, MD, PhD

Latest:

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma

Sander Bach, MD, PhD

Latest:

Dr. Bach on Examining ctDNA in CRC

Sander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.

Kelly Weaver, NP, DNP

Latest:

The Potential of Modified Treatment Regimens in AYA ALL

Experts on AYA ALL discuss the potential applicability of modified treatment regimens and the importance of multidisciplinary collaboration to meet the unique needs of patients.

Rhonda Cooper

Latest:

Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy

Camidge and Cooper discuss Cooper’s career as a hospital chaplain, the focus of her writing, and the importance of meeting patients where they are.

Firas El Chaer, MD

Latest:

Dr. El Chaer on the Role of Next-Generation Sequencing in MPNs

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Laura Huppert, MD

Laura Huppert, MD, is an assistant professor of medicine in the Department of Medicine at the University of California, San Francisco School of Medicine

Latest:

Primary Results from ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan vs Chemotherapy in Patients with Previously Untreated Advanced Triple-Negative Breast Cancer Who Are Unable to Receive PD-(L)1 Inhibitors

Laura Huppert, MD discusses LBA20 – primary results from ASCENT-03: a randomized phase 3 study of Sacituzumab Govitecan (SG) vs chemotherapy (Chemo) in patients (Pts) with previously untreated Advanced Triple-Negative Breast Cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)

Matthew J. Baker, PhD

Latest:

Dr Baker on the EMBRACE Trial of the Dxcover Liquid Biopsy in Brain Cancer

Matthew J. Baker, PhD, discusses the ongoing investigation of the Dxcover Liquid Biopsy for patients with brain cancer in the EMBRACE study.

Naoki Niikura, MD, PhD

Latest:

Dr Niikura on T-DXd in Patients With HER2+ Breast Cancer With Brain Metastases and Leptomeningeal Disease

Naoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.

Kathryn Hitchcock, MD, PhD

Latest:

Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRC

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer

Sarah E. S. Leary, MD, MS

Latest:

Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma

Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

Mark R. Albertini, MD

Latest:

Stage Is Set for Continued Progress in the Melanoma Clinic

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

Taymaa May, MD, MSc

Taymaa May, MD, MSc, is the director of Ovarian Cancer Surgery in the Division of Surgical Oncology at the Brigham and Women’s Hospital in Boston, as well as an associate professor at Harvard Medical School.

Latest:

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

Manisha Palta, MD

Latest:

Dr. Palta on the Clinical Implications of the NRG/RTOG 1112 Trial in HCC

Manisha Palta, MD, discusses the clinical implications of the phase 3 NRG/RTOG 1112 trial in patients with locally advanced hepatocellular carcinoma.

Maria Carmela Piccirillo, MD

Latest:

Dr. Piccirillo on the Safety Profile of Bevacizumab Plus Erlotinib in EGFR+ Nonsquamous NSCLC

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

Dana Zakalik, MD

Latest:

Dr Zakalik on the Role of Genetic Testing to Guide Breast Cancer Treatment

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

Marijo Bilusic, MD, PhD

Latest:

Dr Bilusic on the Investigation of Enfortumab Vedotin in Rare GU Cancers

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Evan S. Wu, MD, PhD

Evan S. Wu, MD, PhD, is an assistant professor at the University of Hawai’i Cancer Center

Latest:

Accelerating US Oncology Drug Development Using Chinese First-in-Human Data

Evan S. Wu, Md, PhD, concludes a three-part series highlighting the translatability of Chinese clinical data into US regulatory pathways.

Sunnie Kim, MD

Latest:

Dr. Kim on Tislelizumab in Advanced ESCC

Sunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma.